Oruka Therapeutics (NASDAQ:ORKA) Lowered to “Sell” Rating by Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other analysts have also issued reports on ORKA. BTIG Research began coverage on shares of Oruka Therapeutics in a research report on Thursday, May 22nd. They set a “buy” rating for the company. Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research report on Thursday, May 15th. One analyst has rated the stock with a sell rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $40.38.

Oruka Therapeutics Stock Down 2.4%

Shares of ORKA stock opened at $12.56 on Friday. The company has a 50 day moving average price of $10.28 and a 200-day moving average price of $13.02. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The firm has a market capitalization of $470.26 million, a PE ratio of -2.01 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. Analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ORKA. AlphaCentric Advisors LLC bought a new position in shares of Oruka Therapeutics during the fourth quarter worth $119,000. Charles Schwab Investment Management Inc. bought a new position in shares of Oruka Therapeutics during the fourth quarter worth $303,000. Vanguard Group Inc. boosted its position in shares of Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock worth $31,231,000 after acquiring an additional 1,572,853 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Oruka Therapeutics during the fourth quarter worth $54,000. Finally, Wellington Management Group LLP boosted its position in shares of Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock worth $1,844,000 after acquiring an additional 12,952 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.